Previous Study: TRIO 013
Next Study: TRIO 015

Studies & Results

TRIO 014

A randomized, double-blind, placebo controlled, multi-center, Phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor Type 1 receptor (IGF-1R) to first-line chemotherapy in patients with optimally debulked (< 1cm) epithelial ovarian cancer

View FDA Study View EU Study

Presentations

ASCO Annual Meeting, 2014

Konecny GE, Haluska P, Janicke F, et al

A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org